Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Net Income: 2020-2024

Historic Net Income for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to -$241.6 million.

  • NewAmsterdam Pharma Co N.V's Net Income fell 332.54% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$221.1 million, marking a year-over-year decrease of 11.15%. This contributed to the annual value of -$241.6 million for FY2024, which is 36.54% down from last year.
  • As of FY2024, NewAmsterdam Pharma Co N.V's Net Income stood at -$241.6 million, which was down 36.54% from -$176.9 million recorded in FY2023.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Net Income peaked at -$6.6 million during FY2020, and registered a low of -$241.6 million during FY2024.
  • Moreover, its 3-year median value for Net Income was -$176.9 million (2023), whereas its average is -$147.1 million.
  • Its Net Income has fluctuated over the past 5 years, first soared by 45.83% in 2022, then tumbled by 681.73% in 2023.
  • NewAmsterdam Pharma Co N.V's Net Income (Yearly) stood at -$6.6 million in 2020, then tumbled by 536.57% to -$41.8 million in 2021, then spiked by 45.83% to -$22.6 million in 2022, then plummeted by 681.73% to -$176.9 million in 2023, then crashed by 36.54% to -$241.6 million in 2024.